Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects.

Ramos Ade T, Homem KS, Suchecki D, Tufik S, Troncone LR.

Behav Brain Res. 2014 May 15;265:69-75. doi: 10.1016/j.bbr.2014.02.024.

PMID:
24569014
3.

An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.

Serradeil-Le Gal C, Wagnon J 3rd, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A.

CNS Drug Rev. 2005 Spring;11(1):53-68. Review.

4.

Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.

Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ, Mullins DE, Guzzi MF, Parker EM, Varty GB.

Pharmacol Biochem Behav. 2007 Mar;86(3):431-40.

PMID:
17291571
5.

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5.

6.

Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.

Salomé N, Stemmelin J, Cohen C, Griebel G.

Psychopharmacology (Berl). 2006 Aug;187(2):237-44.

PMID:
16779555
7.

Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.

Lelas S, Wong H, Li YW, Heman KL, Ward KA, Zeller KL, Sieracki KK, Polino JL, Godonis HE, Ren SX, Yan XX, Arneric SP, Robertson DW, Hartig PR, Grossman S, Trainor GL, Taub RA, Zaczek R, Gilligan PJ, McElroy JF.

J Pharmacol Exp Ther. 2004 Apr;309(1):293-302.

8.

Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.

Iijima M, Yoshimizu T, Shimazaki T, Tokugawa K, Fukumoto K, Kurosu S, Kuwada T, Sekiguchi Y, Chaki S.

Br J Pharmacol. 2014 Jul;171(14):3511-25. doi: 10.1111/bph.12699.

9.

Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist.

Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE.

Neuropsychopharmacology. 2002 Aug;27(2):194-202.

10.
14.

Effects of the vasopressin (V1b) receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, on FG 7142-induced increase in acetylcholine and norepinephrine release in the rat.

Claustre Y, Rouquier L, Desvignes C, Leonetti M, Montégut J, Aubin N, Allouard N, Bougault I, Oury-Donat F, Steinberg R.

Neuroscience. 2006 Sep 1;141(3):1481-8.

PMID:
16781820
15.

Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.

Griebel G, Stemmelin J, Gal CS, Soubrié P.

Curr Pharm Des. 2005;11(12):1549-59. Review.

PMID:
15892661
16.

Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice.

Bhutada P, Mundhada Y, Bansod K, Ubgade A, Quazi M, Umathe S, Mundhada D.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):955-60. doi: 10.1016/j.pnpbp.2010.04.025.

PMID:
20447436
17.

Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety.

Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP.

Brain Res. 2001 Jun 1;902(2):135-42.

PMID:
11384606
18.
19.

Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.

Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E.

Neuropharmacology. 2006 Sep;51(3):578-86.

PMID:
16828124
20.

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.

Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, Holsboer F.

J Psychiatr Res. 2000 May-Jun;34(3):171-81.

PMID:
10867111
Items per page

Supplemental Content

Support Center